Tag Wart Remover

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the removal of genital warts, plantar warts, and common warts. Common warts are characterized by their rough, cauliflower-like surface appearance, while plantar warts are specifically located on the bottom of the foot, presenting with tenderness and an interruption of the footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. It is recommended to soak the wart in warm water for approximately 5 minutes to facilitate the process. After soaking, the area must be dried completely.

Using an applicator, such as a cotton swab, a layer of ointment should be applied to sufficiently cover each wart. It is important to allow the ointment to fully absorb into the skin. If necessary, the treated area may be covered with a bandage.

This procedure should be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in patients with diabetes or poor blood circulation due to the potential for exacerbating these conditions.

Additionally, the product should not be used if discomfort persists. Contact with the eyes must be avoided; in the event of exposure, the eyes should be flushed with water for 15 minutes. Inhalation of vapors should also be avoided to prevent respiratory irritation.

Warnings and Precautions

For external use only. It is imperative to keep the product away from fire and flame to prevent any potential hazards. Additionally, this product should be stored out of reach of children to avoid accidental exposure.

In the event of ingestion, immediate medical assistance is required. Healthcare professionals should advise patients to contact emergency medical services or poison control at 1-800-222-1222 without delay.

Patients should be instructed to discontinue use and consult their healthcare provider if discomfort persists. Special caution is advised for individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects. Regular monitoring of these patients is recommended to ensure their safety while using this product.

Side Effects

Patients should be aware that the product is for external use only. It is imperative to keep the product away from fire and flame to prevent any potential hazards. Additionally, it should be kept out of reach of children to avoid accidental ingestion or misuse.

In the event that discomfort persists after application, patients are advised to discontinue use. Special caution is warranted for individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse reactions.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Tag Wart Remover (salicylic acid 10%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this product for external application only. It is important to ensure that children do not touch the treated area. Care should be taken to avoid contact with the eyes; in the event of exposure, the eye should be flushed with water for 15 minutes. If the product is ingested, immediate medical attention should be sought by calling 1-800-222-1222.

Prior to application, the affected area should be washed, and warts may be soaked in warm water for 5 minutes. The area must be dried thoroughly before treatment. Using a cotton swab applicator, a layer of ointment should be applied to sufficiently cover each wart. The ointment should be allowed to fully absorb, and a bandage may be applied as needed. This procedure may be repeated once or twice daily as necessary, continuing for up to 12 weeks until the wart is removed.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The product has not been specifically studied in pregnant patients, and no explicit warnings or precautions regarding its use during pregnancy are provided in the prescribing information. There are no stated safety concerns or contraindications for use during pregnancy, and no dosage modifications for pregnant individuals are mentioned. Additionally, the insert does not include any special precautions regarding the use of this product in pregnant patients. Healthcare professionals should consider the lack of specific data when prescribing this product to women of childbearing potential.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there are no statements concerning the potential for excretion in breast milk or any associated risks to breastfed infants during lactation.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement standard supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical attention by calling 1-800-222-1222 if the product is swallowed. Patients should be instructed to discontinue use if they experience any discomfort that persists. It is important to inform patients that they should stop using the product if they have diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Providers should emphasize the importance of avoiding contact with the eyes. In the event that the product comes into contact with the eyes, patients should be instructed to flush the eyes with water for at least 15 minutes. Additionally, patients should be cautioned against inhaling vapors from the product to prevent respiratory irritation.

Patients should be reminded to cap the tube tightly after each use to maintain product integrity. Furthermore, it is essential to advise patients to store the product out of direct sunlight and at room temperature, away from heat sources, to ensure its effectiveness and safety.

Storage and Handling

The product is supplied in a tube that must be capped tightly after each use to maintain its integrity. It should be stored at room temperature, away from heat sources, and protected from direct sunlight. Additionally, it is essential to keep the product away from fire and flame to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically, with a recommended frequency of once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should advise patients that the product is for external use only and must be kept away from fire and flame. It is important to ensure that children do not touch the product and to avoid contact with the eyes; in case of eye exposure, patients should flush with water for 15 minutes. Inhalation of vapors should be avoided, and the tube should be capped tightly and stored at room temperature, away from direct sunlight and heat.

Patients should be counseled to seek immediate medical attention if the product is swallowed, using the contact number 1-800-222-1222. Additionally, if discomfort persists or if the patient has diabetes or poor blood circulation, they should consult a healthcare professional.

Drug Information (PDF)

This file contains official product information for Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)